71_CD
Cambridge_NN
Antibody_NN
Technology_NN
Group_NN
plc_NN
Shareholder_NN
Information_NOMZ
The_DT
share_NN
price_NN
is_VPRT [BEMA]
obtainable_PRED
from_PIN
the_DT
following_GER
:_:
US_FPP1
Depositary_NN
Financial_NN
Times_NN
,_,
Daily_NN
Telegraph_NN
,_,
The_DT
Independent_NN
,_,
The_NN
Bank_NN
of_PIN
New_NN
York_NN
Cambridge_NN
Evening_GER
News_NN
,_,
The_DT
Guardian_NN
,_,
Daily_NN
Express_NN
._.
Investor_NN
Relations_NOMZ
PO_NN
Box_NN
11258_CD
London_NN
Stock_NN
Exchange_NN
Church_NN
Street_NN
Station_NOMZ
mnemonic_JJ
CAT_NN
New_NN
York_NN
,_,
NY10286-1258_NN
,_,
US_FPP1
NASDAQ_NN
Investor_NN
relations_NOMZ
Information_NOMZ
on_PIN
CAT_NN
is_VPRT [BEMA]
available_JJ
online_NN
via_PIN
the_DT
internet_NN
at_PIN
mnemonic_JJ
CATG_NN
www_NN
._.
com_NN
Announcements_NOMZ
Security_NOMZ
analysts_NN
and_PHC
investment_NOMZ
professionals_NN
should_NEMD
direct_VB
their_TPP3
First_JJ
quarter_NN
mid_VBD
February_NN
enquiries_NN
in_PIN
the_DT
first_JJ
instance_NN
to_TO
:_:
Interim_NN
mid_VBD
May_POMD
UK_NN
Europe_NN
Third_NN
quarter_NN
early_TIME
September_NN
Final_NN
mid_VBD
November_NN
Corporate_NN
Communications_NOMZ
Cambridge_NN
Antibody_NN
Technology_NN
Group_NN
plc_NN
Shareholders_NN
Milstein_NN
Building_GER
There_EX
are_VPRT
approximately_RB
2,300_CD
registered_VBN
shareholders_NN
._.
Granta_NN
Park_NN
Cambridge_NN
CB1_NN
6GH_NN
,_,
UK_NN
Company_NN
Secretary_NN
and_CC
registered_VBN
office_NN
US_FPP1
Diane_NN
Mellett_NN
LLB_NN
JD_NN
Cambridge_NN
Antibody_NN
Technology_NN
Group_NN
plc_NN
The_DT
Trout_NN
Group_NN
LLC_NN
Milstein_NN
Building_GER
740_NN
Broadway_NN
,_,
Suite_NN
903_CD
Granta_NN
Park_NN
New_NN
York_NN
,_,
NY10003_NN
,_,
US_FPP1
Cambridge_NN
CB1_NN
6GH_NN
,_,
UK_NN
Registered_NN
number_NN
3234033_CD
Registrars_NN
Computershare_NN
Investor_NN
Services_NN
PLC_NN
PO_NN
Box_NN
82_CD
The_DT
Pavilions_NN
Bridgwater_NN
Road_NN
Bristol_NN
BS99_NN
7NH_NN
,_,
UK_NN
Tel_NN
0870 702 0000_CD
PFIC_NN
Annual_JJ
Information_NOMZ
Statement_NOMZ
Cambridge_NN
Antibody_NN
Technology_NN
Group_NN
plc_NN
The_DT
following_VBG
information_NOMZ
applies_VPRT
to_PIN
United_NN
States_NN
shareholders_NN
only_DWNT
._.
For_PIN
the_DT
year_NN
ended_VBD
30_CD
September_NN
2002_CD
,_,
we_FPP1
believe_VPRT [PRIV]
that_THVC
the_DT
Company_NN
was_VBD [BEMA]
not_XX0
a_DT
Passive_NN
Foreign_NN
Investment_NOMZ
Corporation_NOMZ
PFIC_NN
as_IN
defined_VBN
by_PIN
Section_NOMZ
1297_CD
of_PIN
the_DT
United_NN
States_NN
Code_NN
._.
This_DEMO
conclusion_NN
is_VPRT [BEMA]
a_DT
factual_JJ
determination_NOMZ
that_DEMP
is_VPRT [PASS]
made_VBN
annually_RB
and_ANDC
therefore_CONJ
may_POMD
be_VB [BEMA]
subject_PRED
to_TO
change_VB
in_PIN
the_DT
future_NN
._.
As_IN
the_DT
Company_NN
was_VBD [BEMA]
at_PIN
one_CD
time_NN
a_DT
PFIC_NN
we_FPP1
provide_VPRT
the_DT
following_VBG
information_NOMZ
._.
Fiscal_JJ
year_NN
ended_VBD
30_CD
September_NN
2002_CD
1_CD
This_DEMO
information_NOMZ
is_VPRT
being_VBG [PASS]
provided_VBN
pursuant_JJ
to_PIN
Section_NOMZ
1.1295-1T_NN
of_PIN
the_DT
United_NN
States_NN
Treasury_NN
Regulations_NOMZ
._.
2_CD
This_DEMO
PFIC_NN
Annual_JJ
Information_NOMZ
Statement_NOMZ
applies_VPRT
to_PIN
the_DT
financial_JJ
year_NN
of_PIN
the_DT
Company_NN
beginning_VBG [WZPRES]
1_CD
October_NN
2001_CD
and_CC
ending_VBG
30_CD
September_NN
2002_CD
._.
3_CD
The_DT
Company_NN
had_VBD
negative_JJ
ordinary_JJ
earnings_GER
and_CC
no_SYNE
net_JJ
capital_NN
gain_NN
for_PIN
the_DT
taxable_JJ
year_NN
indicated_VBD [PRIV]
above_PLACE
._.
4_CD
During_PIN
the_DT
year_NN
no_SYNE
actual_JJ
or_CC
deemed_VBD [PRIV] [THATD]
distributions_NOMZ
were_VBD [PASS]
made_VBN
._.
5_CD
The_DT
Company_NN
has_VPRT [PEAS]
given_VBN
the_DT
information_NOMZ
set_VBN [WZPAST]
forth_RB
in_PIN
paragraphs_NN
14_CD
above_PLACE
to_TO
enable_VB
the_DT
shareholder_NN
to_TO
establish_VB [PRIV]
that_THVC
the_DT
Companys_NN
ordinary_JJ
earnings_GER
and_CC
net_JJ
capital_NN
gain_NN
are_VPRT [PASS]
computed_VBN
in_PIN
accordance_NN
with_PIN
US_FPP1
income_NN
tax_NN
principles_NN
and_CC
to_TO
determine_VB [SUAV] [PRIV]
the_DT
shareholders_NN
pro_PIN
rata_JJ
share_NN
thereof_RB
._.
72_CD
Cambridge_NN
Antibody_NN
Technology_NN
Group_NN
plc_NN
Glossary_NN
Please_UH
use_VB
this_DEMO
glossary_NN
of_PIN
terms_NN
to_TO
give_VB
you_SPP2
a_DT
better_JJ
understanding_GER
of_PIN
our_FPP1
business_NOMZ
._.
Acute_JJ
Respiratory_NN
Distress_NN
Syndrome_NN
ARDS_NN
A_NN
severe_JJ
form_NN
of_PIN
acute_JJ
failure_NN
Nasal_NN
patency_NN
The_DT
openness_NOMZ
of_PIN
airways_NN
in_PIN
the_DT
nose_NN
._.
of_PIN
lung_NN
function_NOMZ
which_WDT [WHSUB]
can_POMD
occur_VB
after_IN
trauma_NN
,_,
sepsis_NN
or_CC
inhalation_NOMZ
of_PIN
a_DT
toxic_JJ
substance_NN
._.
Ocular_JJ
Of_PIN [STPR]
,_,
or_CC
relating_VBG
to_TO
,_,
the_DT
eye_NN
._.
A_DT
negotiable_JJ
US_FPP1
certificate_NN
representing_VBG [WZPRES]
ownership_NN
Orphan_NN
Drug_NN
status_NN
Denotes_VPRT
a_DT
drug_NN
for_PIN
a_DT
rare_JJ
disease_NN
less_RB
than_PIN
5_CD
per_PIN
10,000_CD
of_PIN
shares_NN
in_PIN
a_DT
non-US_FPP1
corporation_NOMZ
,_,
ADRs_NN
are_VPRT [PASS]
quoted_VBN
and_PHC
traded_VBN
in_PIN
US_FPP1
dollars_NN
on_PIN
US_FPP1
population_NOMZ
in_PIN
Europe_NN
._.
Orphan_JJ
designation_NOMZ
brings_VPRT
commercial_JJ
benefits_NN
to_PIN
the_DT
company_NN
securities_NOMZ
markets_NN
._.
CATs_NN
ADRs_NN
are_VPRT [PASS]
quoted_VBN
on_PIN
the_DT
NASDAQ_NN
National_NN
Market_NN
and_CC
one_CD
developing_VBG
the_DT
drug_NN
._.
CAT_NN
ADR_NN
represents_VPRT
one_CD
ordinary_JJ
share_NN
in_PIN
CAT_NN
._.
Phakotrabeclectomy_NN
Combined_NN
surgery_NN
to_TO [SPIN]
simultaneously_TIME
treat_VB
glaucoma_NN
Agonistic_NN
A_NN
positive_JJ
response_NN
induced_VBN [WZPAST]
by_PIN
the_DT
binding_JJ
of_PIN
a_DT
target_NN
molecule_NN
to_PIN
a_DT
cell_NN
and_CC
a_DT
cataract_NN
._.
Phage_NN
Abbreviation_NOMZ
for_PIN
bacteriophage_NN
,_,
a_DT
filamentous_JJ
virus_NN
that_TSUB
infects_VPRT
bacteria_NN
._.
Allergic_JJ
disease_NN
disorder_NN
Conditions_NOMZ
caused_VBN [WZPAST]
by_PIN
an_DT
overreaction_NOMZ
of_PIN
the_DT
immune_JJ
system_NN
to_PIN
foreign_JJ
substances_NN
which_WDT [WHSUB]
are_VPRT [SPAU] [PASS]
usually_RB
considered_VBN [PRIV]
to_TO
be_VB [BEMA]
harmless_PRED
._.
Phage_NN
display_NN
CATs_NN
proprietary_JJ
technology_NN
in_PIN
which_WDT [PIRE]
antibodies_NN
are_VPRT [PASS]
displayed_VBN
on_PIN
the_DT
tip_NN
of_PIN
a_DT
phage_JJ
virus_NN
._.
Pharmacokinetics_NN
The_NN
study_NN
of_PIN
the_DT
time_NN
course_NN
of_PIN
a_DT
drug_NN
in_PIN
the_DT
body_NN
following_VBG [WZPRES]
Antibody_NN
A_NN
protein_NN
produced_VBN [WZPAST]
by_PIN
B-lymphocytes_NN
white_JJ
blood_NN
cells_NN
of_PIN
the_DT
immune_JJ
administration_NOMZ
._.
system_NN
,_,
which_WDT [SERE]
specifically_RB
recognizes_VPRT [PRIV]
a_DT
target_NN
molecule_NN
known_VBN [PRIV]
as_IN
an_DT
antigen_NN
._.
Phase_NN
I_FPP1
clinical_JJ
trial_NN
A_DT
first_JJ
in_PIN
man_NN
study_NN
conducted_VBN
to_TO
determine_VB [SUAV] [PRIV]
the_DT
biological_JJ
Antigen_NN
A_NN
molecule_NN
recognized_VBN [PRIV] [WZPAST]
by_PIN
an_DT
antibody_NN
._.
effects_NN
of_PIN
a_DT
drug_NN
,_,
especially_RB
its_PIT
safety_NN
,_,
tolerability_NOMZ
and_PHC
pharmacokinetics_NN
._.
Autoimmune_JJ
disease_NN
disorder_NN
Conditions_NOMZ
which_WDT [WHSUB]
occur_VPRT
when_RB
the_DT
human_JJ
immune_JJ
Phase_NN
I_FPP1
II_NN
clinical_JJ
trial_NN
Early_TIME
study_NN
in_PIN
patients_NN
with_PIN
the_DT
disease_NN
for_PIN
which_WDT [PIRE]
the_DT
product_NN
system_NN
reacts_VPRT
against_PIN
a_DT
component_NN
of_PIN
the_DT
human_JJ
body_NN
._.
candidate_NN
is_VPRT
being_VBG [PASS]
developed_VBN
to_TO
determine_VB [SUAV] [PRIV]
safety_NN
and_CC
preliminary_JJ
efficacy_NN
._.
B-Lymphocyte_JJ
stimulator_NN
BLyS_NN
A_NN
protein_NN
which_WDT [WHSUB]
stimulates_VPRT
B-lymphocytes_NN
to_PIN
Phase_NN
III_NN
clinical_JJ
trial_NN
Trials_NN
with_PIN
larger_JJ
patient_NN
numbers_NN
to_TO
confirm_VB [PUBV]
a_DT
drugs_NN
efficacy_NN
produce_VPRT
antibodies_NN
._.
This_DEMP
is_VPRT [BEMA]
the_DT
last_JJ
phase_NN
of_PIN
trials_NN
prior_RB
to_TO
filing_VBG
for_PIN
market_NN
approval_NN
._.
Cirrhosis_NN
A_NN
condition_NOMZ
of_PIN
chronic_JJ
scarring_GER
of_PIN
the_DT
liver_NN
,_,
characterised_VBN [PASTP]
by_PIN
the_DT
presence_NN
Pulmonary_NN
Relating_VBG [WZPRES]
to_PIN
the_DT
lung_NN
._.
of_PIN
fibrous_JJ
tissue_NN
,_,
which_WDT [SERE]
destroys_VPRT
the_DT
liver_NN
architecture_NN
and_CC
interferes_VPRT
with_PIN
normal_JJ
liver_NN
function_NOMZ
._.
Rheumatoid_JJ
arthritis_NN
A_DT
condition_NOMZ
characterised_VBN [WZPAST]
by_PIN
chronic_JJ
inflammation_NOMZ
and_CC
gradual_JJ
destruction_NOMZ
of_PIN
the_DT
joints_NN
._.
Crohns_NN
disease_NN
A_DT
chronic_JJ
inflammatory_JJ
disorder_NN
of_PIN
the_DT
bowels_NN
._.
Scleroderma_NN
An_DT
autoimmune_JJ
disease_NN
of_PIN
the_DT
connective_JJ
tissues_NN
which_WDT [WHSUB]
affects_VPRT
blood_NN
Cytokines_NN
Small_NN
protein_NN
molecules_NN
that_TSUB
are_VPRT [BYPA]
released_VBN
by_PIN
cells_NN
which_WDT [WHSUB]
affect_VPRT
the_DT
vessels_NN
and_CC
is_VPRT [BYPA]
characterised_VBN
by_PIN
thickening_VBG
of_PIN
the_DT
skin_NN
and_PHC
fibrosis_NN
of_PIN
the_DT
internal_JJ
organs_NN
behavior_NN
of_PIN
other_JJ
cells_NN
and_CC
regulate_VB
biological_JJ
processes_NN
._.
TM_NN
D2E7_NN
Original_NN
codename_NN
for_PIN
Humira_NN
adalimumab_NN
._.
Systemic_JJ
lupus_NN
erythematosus_VPRT
SLE_NN
Often_RB
known_VBN [PRIV]
as_IN
lupus_NN
,_,
one_CD
of_PIN
a_DT
group_NN
of_PIN
Diabetic_NN
nephropathy_NN
Chronic_NN
kidney_NN
disease_NN
,_,
characterised_VBN [PASTP]
by_PIN
the_DT
leaking_VBG
of_PIN
severe_JJ
autoimmune_JJ
diseases_NN
characterised_VBN [WZPAST]
by_PIN
the_DT
production_NOMZ
of_PIN
auto_NN
antibodies_NN
which_WDT [WHOBJ]
protein_NN
into_PIN
the_DT
urine_NN
,_,
which_WDT [SERE]
occurs_VPRT
as_CONJ
a_NULL
result_NULL
of_PIN
long-standing_JJ
diabetes_NN
._.
can_POMD
damage_VB
internal_JJ
organs_NN
such_JJ
as_IN
the_DT
kidney_NN
._.
Efficacy_NN
The_NN
measure_NN
of_PIN
the_DT
effectiveness_NOMZ
of_PIN
a_DT
drug_NN
in_PIN
treating_VBG
a_DT
particular_JJ
condition_NOMZ
._.
TGF_NN
Transforming_VBG [WZPRES]
growth_NN
factor_NN
beta_JJ
TGF_NN
is_VPRT [BEMA]
a_DT
family_NN
of_PIN
multifunctional_JJ
biological_JJ
molecules_NN
,_,
excess_JJ
production_NOMZ
of_PIN
which_WDT [PIRE]
is_VPRT [PASS]
associated_VBN
with_PIN
fibrosis_NN
and_PHC
scarring_GER
._.
Eosinophil_NN
A_NN
type_NN
of_PIN
white_JJ
blood_NN
cell_NN
,_,
containing_VBG
eosinophilic_JJ
granules_NN
,_,
which_WDT [SERE]
are_VPRT [SPAU] [PASS]
particularly_RB
involved_VBN
in_PIN
allergic_JJ
disorders_NN
._.
TGF_NN
The_NN
form_NN
of_PIN
TGF_NN
that_DEMP
is_VPRT [SPAU] [PASS]
strongly_AMP
linked_VBN
to_PIN
fibrosis_NN
and_PHC
scarring_GER
of_PIN
the_DT
skin_NN
as_IN
1_CD
well_RB
as_IN
most_EMPH
internal_JJ
organs_NN
._.
Eotaxin_NN
A_NN
protein_NN
that_TSUB
attracts_VPRT
eosinophils_NN
into_PIN
tissues_NN
,_,
where_RB
they_TPP3
can_POMD
degranulate_VB
and_PHC
cause_VB
tissue_NN
damage_NN
._.
TGF_NN
The_NN
form_NN
of_PIN
TGF_NN
that_DEMP
is_VPRT [SPAU] [PASS]
strongly_AMP
associated_VBN
with_PIN
scarring_VBG
in_PIN
and_CC
around_PLACE
2_CD
the_DT
eye_NN
._.
Fibrosis_NN
A_NN
pathological_JJ
process_NN
characterised_VBN [WZPAST]
by_PIN
the_DT
proliferation_NOMZ
of_PIN
fibrous_JJ
connective_JJ
tissue_NN
,_,
the_DT
main_JJ
component_NN
of_PIN
scar_NN
tissue_NN
,_,
which_WDT [SERE]
may_POMD
occur_VB
as_CONJ
a_NULL
result_NULL
of_PIN
repeated_VBN [PUBV]
TNF_NN
Tumour_NN
necrosis_NN
factor_NN
alpha_NN
TNF_NN
belongs_VPRT
to_PIN
the_DT
cytokine_NN
family_NN
of_PIN
injury_NN
to_PIN
a_DT
tissue_NN
._.
It_PIT
has_VPRT
pro-inflammatory_JJ
effects_NN
and_ANDC
when_RB
produced_VBN
excessively_RB
is_VPRT [BEMA]
responsible_PRED
for_PIN
increasing_VBG
tissue_NN
damage_NN
in_PIN
disorders_NN
such_JJ
as_IN
rheumatoid_JJ
arthritis_NN
._.
Glaucoma_NN
A_NN
group_NN
of_PIN
eye_NN
conditions_NOMZ
in_PIN
which_WDT [PIRE]
the_DT
optic_JJ
nerve_NN
is_VPRT [SPAU] [PASS]
permanently_RB
damaged_VBN
at_PIN
the_DT
point_NN
where_RB
it_PIT
leaves_VPRT
the_DT
eye_NN
,_,
resulting_VBG [PRESP]
in_PIN
significant_JJ
loss_NN
of_PIN
vision_NN
or_CC
blindness_NOMZ
._.
Topical_JJ
medication_NOMZ
Medication_NOMZ
applied_VBD
to_PIN
the_DT
surface_NN
as_IN
opposed_VBN
to_PIN
injection_NOMZ
The_DT
major_JJ
cause_NN
of_PIN
the_DT
damage_NN
is_VPRT [PASS]
thought_VBN [PRIV]
to_TO
be_VB [PASS]
raised_VBN
pressure_NN
inside_PLACE
the_DT
eye_NN
._.
Glioma_NN
A_NN
type_NN
of_PIN
malignant_JJ
brain_NN
tumor_NN
._.
Trabeculectomy_NN
The_NN
commonest_JJ
type_NN
of_PIN
surgical_JJ
operation_NOMZ
performed_VBN [WZPAST]
on_PIN
patients_NN
with_PIN
glaucoma_NN
to_PIN
lower_JJ
intraocular_JJ
pressure_NN
._.
Haematopoietic_NN
Relating_VBG [WZPRES]
to_TO
stem_VB
cells_NN
from_PIN
which_WDT [PIRE]
all_QUAN
blood_NN
cells_NN
are_VPRT [PASS]
derived_VBN
._.
TRAIL-R1_CD
R2_NN
Proteins_NN
expressed_VBD
on_PIN
the_DT
surface_NN
of_PIN
a_DT
number_NN
of_PIN
cancer_NN
cells_NN
which_WDT [WHOBJ]
,_,
TM_NN
Humira_NN
D2E7_NN
A_NN
human_JJ
monoclonal_NN
anti-TNF_JJ
antibody_NN
developed_VBD
for_PIN
the_DT
when_RB
triggered_VBN
,_,
induce_VB
programmed_JJ
cell_NN
death_NN
apoptosis_NN
._.
Lymphocyte_NN
A_NN
type_NN
of_PIN
white_JJ
blood_NN
cell_NN
._.
A_DT
sub-class_JJ
known_VBN [PRIV]
as_IN
B-lymphocytes_NN
produce_VPRT
antibodies_NN
._.
Mast_NN
cells_NN
Tissue_NN
based_VBN
cells_NN
important_JJ
in_PIN
allergic_JJ
and_PHC
inflammatory_JJ
reactions_NOMZ
._.
Microarray_NN
A_NN
flat_JJ
,_,
solid_JJ
support_NN
with_PIN
a_DT
large_JJ
number_NN
of_PIN
ordered_VBN [SUAV]
,_,
densely_RB
packed_JJ
molecules_NN
,_,
usually_RB
protein_NN
or_CC
DNA_NN
,_,
arranged_VBN [SUAV] [PASTP]
on_PIN
its_PIT
surface_NN
._.
Monoclonal_NN
antibody_NN
An_DT
antibody_NN
derived_VBN [WZPAST]
from_PIN
clones_NN
of_PIN
a_DT
single_JJ
cell_NN
:_:
all_QUAN
molecules_NN
have_VPRT
identical_JJ
antigen_NN
binding_JJ
sites_NN
._.
Highlights_NN
of_PIN
the_DT
Year_NN
Chairmans_NN
Statement_NOMZ
02_CD
Abbott_NN
made_VBD
regulatory_JJ
submissions_NN
in_PIN
the_DT
US_FPP1
and_PHC
Europe_NN
for_PIN
marketing_GER
approval_NN
of_PIN
Clinical_JJ
and_PHC
Pre-Clinical_JJ
Pipeline_NN
04_CD
Introduction_NOMZ
from_PIN
the_DT
Chief_NN
Executive_NN
Officer_NN
05_CD
Humira_NN
D2E7_NN
,_,
a_DT
human_JJ
monoclonal_JJ
antibody_NN
anti-TNF_JJ
therapy_NN
for_PIN
rheumatoid_JJ
Review_NN
of_PIN
the_DT
Year_NN
06_CD
arthritis_NN
,_,
isolated_VBN
and_PHC
optimised_VBN
by_PIN
CAT_NN
in_PIN
collaboration_NOMZ
with_PIN
Abbott_NN
._.
Financial_NN
Review_NN
18_CD
Board_NN
of_PIN
Directors_NN
26_CD
CAT-152_NN
,_,
a_DT
human_JJ
monoclonal_JJ
antibody_NN
against_PIN
TGF_NN
used_VBD
as_IN
an_DT
anti-scarring_JJ
agent_NN
after_IN
2_CD
Senior_JJ
Executives_NN
28_CD
surgery_NN
to_TO
treat_VB
glaucoma_NN
,_,
produced_VBD
encouraging_JJ
Phase_NN
II_NN
clinical_JJ
trial_NN
results_NN
and_PHC
Scientific_NN
Advisory_NN
Board_NN
28_CD
commenced_VBD
pivotal_JJ
International_NN
Phase_NN
III_NN
clinical_JJ
trials_NN
._.
Financial_NN
Statements_NOMZ
29_CD
Directors_NN
Report_NN
30_CD
Orphan_NN
Drug_NN
status_NN
awarded_VBN [WZPAST]
for_PIN
CAT-192_NN
,_,
the_DT
human_JJ
anti-TGF_JJ
monoclonal_JJ
antibody_NN
1_CD
Remuneration_NOMZ
Report_NN
32_CD
being_VBG [PASS]
developed_VBN
with_PIN
Genzyme_NN
as_IN
a_DT
potential_JJ
drug_NN
to_TO
treat_VB
scleroderma_NN
._.
Corporate_JJ
Governance_NN
36_CD
Independent_NN
Auditors_NN
Report_NN
39_CD
CAT-213_NN
,_,
a_DT
human_JJ
anti-eotaxin_JJ
monoclonal_JJ
antibody_NN
shows_VPRT [PRIV]
encouraging_JJ
results_NN
in_PIN
a_DT
1_CD
Consolidated_NN
Profit_NN
and_PHC
Loss_NN
Account_NN
40_CD
Phase_NN
I_FPP1
II_NN
trial_NN
as_IN
a_DT
potential_JJ
treatment_NOMZ
for_PIN
allergic_JJ
disorders_NN
._.
Consolidated_NN
Statement_NOMZ
of_PIN
Total_NN
Recognised_NN
Gains_NN
and_PHC
Losses_NN
40_CD
TRAIL-R1_CD
mAb_NN
,_,
a_DT
potential_JJ
anti-cancer_JJ
treatment_NOMZ
,_,
entered_VBD
a_DT
Phase_NN
I_FPP1
clinical_JJ
trial_NN
conducted_VBN
Consolidated_NN
Balance_NN
Sheet_NN
41_CD
Company_NN
Balance_NN
Sheet_NN
42_CD
by_PIN
CATs_NN
partner_NN
,_,
HGSI_NN
._.
Consolidated_NN
Cash_NN
Flow_NN
Statement_NOMZ
43_CD
Five_CD
exclusive_JJ
therapeutic_JJ
licences_NN
granted_VBN [SUAV]
:_:
to_PIN
HGSI_NN
three_CD
,_,
Amgen_NN
and_PHC
Wyeth_NN
Research_NN
for_PIN
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
44_CD
Selected_NN
Financial_NN
Data_NN
69_CD
developing_VBG
CAT-derived_JJ
antibodies_NN
against_PIN
a_DT
range_NN
of_PIN
disease-associated_JJ
molecular_JJ
targets_NN
._.
Corporate_JJ
Advisors_NN
70_CD
Shareholder_NN
Information_NOMZ
71_CD
Co-development_NOMZ
collaboration_NOMZ
signed_VBN [WZPAST]
with_PIN
Amrad_NN
._.
Glossary_NN
72_CD
Research_NN
alliance_NN
signed_VBN [WZPAST]
with_PIN
Chugai_NN
,_,
a_DT
leading_VBG
Japanese_JJ
pharmaceutical_JJ
company_NN
and_CC
,_,
since_OSUB
year_NN
end_NN
,_,
a_DT
second_JJ
agreement_NOMZ
with_PIN
Merck_NN
&_CC
Co._NN
._.
Inc._NN
._.
Royalty_NN
obligations_NOMZ
to_PIN
Drug_NN
Royalty_NN
Corporation_NOMZ
bought_VBD
back_RB
._.
Peter_NN
Chambr_NN
appointed_VBN
as_IN
new_JJ
CEO_NN
._.
Design_NN
and_CC
produced_VBN
by_PIN
Radley_NN
Yeldar_NN
Photography_NN
by_PIN
George_NN
Brooks_NN
and_PHC
John_NN
Edwards_NN
Cambridge_NN
Antibody_NN
Technology_NN
Group_NN
plc_NN
Annual_JJ
Report_NN
2002_CD
Cambridge_NN
Antibody_NN
Technology_NN
Group_NN
plc_NN
Cambridge_NN
Antibody_NN
Technology_NN
Group_NN
plc_NN
Milstein_NN
Building_GER
,_,
Granta_NN
Park_NN
,_,
Cambridge_NN
,_,
CB1_NN
6GH_NN
,_,
UK_NN
Annual_JJ
Report_NN
Telephone_NN
:_:
44_CD
0_CD
1223 471 471_CD
Fax_NN
:_:
44_CD
0_CD
1223 471 472_CD
E-mail_NN
:_:
info@cambridgeantibody_NN
._.
